E. W. Alley, J. Lopez, A. Santoro, A. Morosky, S. Saraf et al., Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol, vol.18, issue.5, pp.623-653, 2017.

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.13, issue.24, pp.2342-50, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02284390

H. Arasanz, M. Gato-cañas, M. Zuazo, M. Ibañez-vea, K. Breckpot et al., PD1 signal transduction pathways in T cells, Oncotarget. 1 août, vol.8, issue.31, pp.51936-51981, 2017.

A. Aupérin, L. Péchoux, C. , R. E. Curran, W. J. Furuse et al., Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer, J Clin Oncol. 1 mai, vol.28, issue.13, pp.2181-90, 2010.

C. Bauer, C. Hees, A. Sterzik, F. Bauernfeind, R. Mak'anyengo et al., Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity, J Immunother. avr, vol.38, issue.3, pp.116-142, 2015.

J. Benzaquen, C. Marquette, N. Glaichenhaus, S. Leroy, P. Hofman et al., The biological rationale for immunotherapy in cancer, Rev Mal Respir. févr, vol.35, issue.2, pp.206-228, 2018.

S. Bölükbas, C. Manegold, M. Eberlein, T. Bergmann, A. Fisseler-eckhoff et al., Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy, Lung Cancer. janv, vol.71, issue.1, pp.75-81, 2011.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

R. Bos, K. L. Marquardt, J. Cheung, and L. A. Sherman, Functional differences between low-and high-affinity CD8+ T cells in the tumor environment, OncoImmunology, vol.1, issue.8, pp.1239-1286

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

L. Calabrò, A. Morra, D. Giannarelli, G. Amato, D. 'incecco et al., Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study, Lancet Respir Med, vol.6, issue.6, pp.451-60, 2018.

D. R. Camidge, R. Dziadziuszko, S. Peters, T. Mok, J. Noe et al., Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study, J Thorac Oncol. juill, vol.14, issue.7, pp.1233-1276, 2019.

D. R. Camidge, H. R. Kim, M. Ahn, J. Yang, J. Han et al., Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.22, issue.21, pp.2027-2066, 2018.

C. Cao, D. Tian, J. Park, J. Allan, K. A. Pataky et al., A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma, Lung Cancer. févr, vol.83, issue.2, pp.240-245, 2014.

D. P. Carbone, M. Reck, L. Paz-ares, B. Creelan, L. Horn et al., First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, New England Journal of Medicine. 22 juin, vol.376, issue.25, pp.2415-2441, 2017.

G. L. Ceresoli, P. A. Zucali, A. G. Favaretto, F. Grossi, P. Bidoli et al., Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma, J Clin Oncol. 20 mars, vol.24, issue.9, pp.1443-1451, 2006.

D. S. Chen and I. Mellman, Oncology meets immunology: the cancer-immunity cycle, Immunity. 25 juill, vol.39, issue.1, pp.1-10, 2013.

S. Couraud, V. Westeel, A. Toffart, and P. Souquet, comité de rédaction des référentiels Auvergne Rhône-Alpes en oncologie thoracique. Référentiel sur le cancer bronchique non à petites-cellules : actualisation 2019, 2019.

G. Defossez, L. Guyader-peyrou, S. Uhry, Z. Grosclaude, P. Remontet et al., Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim. Résultats préliminaires. Rapport. Saint-Maurice (Fra) : Santé publique France, 2019.

M. Delaunay, P. Caron, V. Sibaud, C. Godillot, S. Collot et al., Toxicity of immune checkpoints inhibitors, Rev Mal Respir. déc, vol.35, issue.10, pp.1028-1066, 2018.

M. Dietel, L. Bubendorf, A. Dingemans, C. Dooms, G. Elmberger et al., Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group, Thorax. févr, vol.71, issue.2, pp.177-84, 2016.

H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano et al., , pp.7-8

, T-cell apoptosis: a potential mechanism of immune evasion, Nat Med. août, vol.8, issue.8, pp.793-800, 2002.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002.

G. P. Dunn, L. J. Old, and R. D. Schreiber, The three Es of cancer immunoediting, Annu Rev Immunol, vol.22, pp.329-60, 2004.

P. M. Forde, J. E. Chaft, and D. M. Pardoll, Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N Engl J Med, vol.30, issue.9, p.14, 2018.

P. M. Forde, A. Scherpereel, and A. S. Tsao, Use of Immune Checkpoint Inhibitors in Mesothelioma, Curr Treat Options Oncol. 14 févr, vol.20, issue.2, p.18, 2019.

L. M. Francisco, V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman et al., PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, Journal of experimental Medicine, vol.206, issue.13, pp.3015-3044

G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, vol.192, issue.7, pp.1027-1061, 2000.

W. Fridman, M. Dieu-nosjean, F. Pagès, I. Cremer, D. Damotte et al., The immune microenvironment of human tumors: general significance and clinical impact, Cancer Microenviron. août, vol.6, issue.2, pp.117-139, 2013.

S. Gadgeel, S. Peters, T. Mok, A. T. Shaw, D. W. Kim et al., Alectinib versus crizotinib in treatmentnaive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study, Ann Oncol, vol.29, issue.11, pp.2214-2236, 2018.

S. M. Gadgeel, A. T. Shaw, R. Govindan, L. Gandhi, M. A. Socinski et al., Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer, J Clin Oncol, vol.34, issue.34, pp.4079-85, 2016.

J. Gainor, L. Dardaei, S. Yoda, L. Friboulet, I. Leshchiner et al., Molecular Mechanisms of Resistance to First-and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer, 18 juill, vol.6, issue.10, pp.1118-1151, 2016.

J. F. Gainor, A. T. Shaw, L. V. Sequist, X. Fu, C. G. Azzoli et al., EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis, Clin Cancer Res. 15 sept, vol.22, issue.18, pp.4585-93, 2016.

L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, and G. Kroemer, Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents, Cancer Cell. 14 déc, vol.28, issue.6, pp.690-714, 2015.

L. Gandhi, S. Ou, A. T. Shaw, F. Barlesi, A. Dingemans et al., Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria, Eur J Cancer, vol.82, pp.27-33, 2017.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. E. Felip, E. Angelis et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, New England Journal of Medicine. 16 avr, vol.378, issue.22, pp.2078-92, 2018.

P. Giraud, T. Lacornerie, and F. Mornex, Radiotherapy for primary lung carcinoma, Cancer Radiother. sept, vol.20, pp.147-156, 2016.

G. Goss, C. Tsai, F. A. Shepherd, L. Bazhenova, J. S. Lee et al., Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol. déc, vol.17, issue.12, pp.1643-52, 2016.

S. Grover, O. E. Rahma, N. Hashemi, and R. M. Lim, Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management, Am Soc Clin Oncol Educ Book. 23 mai, vol.38, pp.13-22, 2018.

N. Guerra, Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo et al., NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy, Immunity. avr, vol.28, issue.4, pp.571-80, 2008.

A. Guillemin, B. Rousseau, C. Neuzillet, C. Joly, H. Boussion et al.,

, Bull Cancer. mars, vol.104, issue.3, pp.245-57, 2017.

J. L. Gulley, A. Rajan, D. R. Spigel, N. Iannotti, J. Chandler et al., Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): doseexpansion cohort of a multicentre, open-label, phase 1b trial, Lancet Oncol, vol.18, issue.5, pp.599-610, 2017.

J. B. Haanen, .. G. Carbonnel, F. Robert, C. Kerr, K. M. Peters et al., Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.29, issue.4, pp.264-270, 2018.

D. Hanahan, W. Robert, and A. Ra, Hallmarks of cancer: the next generation, Cell. 4 mars, vol.144, issue.5, pp.646-74, 2011.

M. D. Hellmann, N. A. Rizvi, J. W. Goldman, S. N. Gettinger, H. Borghaei et al., Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study, Lancet Oncol, vol.18, issue.1, pp.31-41, 2017.

L. Horn, A. S. Mansfield, A. Szcz?sna, L. Havel, M. Krzakowski et al., First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, N Engl J Med, vol.379, issue.23, pp.2220-2229, 2018.

E. Hui, J. Cheung, J. Zhu, X. Su, M. J. Taylor et al., T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, vol.31, issue.6332, pp.1428-1461, 2017.

A. N. Husain, T. V. Colby, N. G. Ordóñez, T. C. Allen, R. L. Attanoos et al., Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group, Arch Pathol Lab Med. janv, vol.142, issue.1, pp.89-108, 2018.

H. C. Hwang, S. Pyott, S. Rodriguez, A. Cindric, A. Carr et al., BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas, Am J Surg Pathol. mai, vol.40, issue.5, pp.714-722, 2016.

, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking, IARC Monogr Eval Carcinog Risks Hum, vol.83, pp.1-1438, 2004.

, Cancer broncho-pulmonaire : Du diagnostic au suivi, 2016.

D. B. Johnson, J. M. Balko, M. L. Compton, S. Chalkias, J. Gorham et al., Fulminant Myocarditis with Combination Immune Checkpoint Blockade, N Engl J Med, vol.375, issue.18, pp.1749-55, 2016.

J. Remon, N. Reguart, E. Auclin, and B. Besse, Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients, Journal of Thoracic Oncology. 24 févr, vol.14, issue.6, pp.963-970, 2019.

C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig et al., Adaptive immunity maintains occult cancer in an equilibrium state, Nature. 6 déc, vol.450, issue.7171, pp.903-910, 2007.

R. Komaki, Z. Liao, H. Liu, S. Tucker, D. Rice et al., Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to, Int J Radiat Oncol Biol Phys. 1 déc, vol.65, issue.5, pp.1595-1601, 2006.

C. J. Langer, S. M. Gadgeel, H. Borghaei, V. A. Papadimitrakopoulou, A. Patnaik et al., Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study, Lancet Oncol, vol.17, issue.11, pp.1497-508, 2016.

C. K. Lee, Y. Wu, P. N. Ding, S. J. Lord, A. Inoue et al., Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, J Clin Oncol. 10 juin, vol.33, issue.17, pp.1958-65, 2015.

S. M. Lim, H. R. Kim, J. Lee, K. H. Lee, Y. Lee et al., Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement, J Clin Oncol. 10 août, vol.35, issue.23, pp.2613-2621, 2017.

M. Locatelli-sanchez, P. Foucher, M. Pérol, A. Scherpereel, and G. Zalcman, comité de rédaction des référentiels Auvergne Rhône-Alpes en, et al. Référentiel sur le Mésothéliome Malin de la plèvre : actualisation 2019, 2019.

M. Maio, A. Scherpereel, L. Calabrò, J. Aerts, C. Perez et al., Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial, Lancet Oncol, vol.18, issue.9, pp.1261-73, 2017.

D. Makarious, K. Horwood, and J. Coward, Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors, Eur J Cancer, vol.82, pp.128-164, 2017.

C. Manegold, A. Dingemans, J. E. Gray, K. Nakagawa, M. Nicolson et al., The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC, J Thorac Oncol, vol.12, issue.2, pp.194-207, 2017.

J. Mazières, G. Zalcman, L. Crinò, P. Biondani, F. Barlesi et al., Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort, Journal of Clinical Oncology. 20 mars, vol.33, issue.9, pp.992-1001, 2015.

E. L. Mitchell, P. Lau, C. Khoo, D. Liew, J. Leung et al., Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series, Eur J Cancer. déc, vol.105, pp.88-102, 2018.

D. Moir, W. S. Rickert, G. Levasseur, Y. Larose, R. Maertens et al., A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions, Chem Res Toxicol. févr, vol.21, issue.2, pp.494-502, 2008.

Z. Neviere, P. Berthet, F. Polycarpe, C. Dubos-arvis, P. Dô et al., Malignant mesothelioma and constitutional BAP1 gene mutations, Rev Mal Respir. févr, vol.36, issue.2, pp.241-249, 2019.

A. K. Nowak, M. J. Byrne, R. Williamson, G. Ryan, A. Segal et al., A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma, Br J Cancer. 27 août, vol.87, issue.5, pp.491-497, 2002.

, Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, NSCLC Meta-analysis Collaborative Group, vol.383, pp.1561-71, 2014.

Y. Ohe, F. Imamura, N. Nogami, I. Okamoto, T. Kurata et al., Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset, Jpn J Clin Oncol. 1 janv, vol.49, issue.1, pp.29-36, 2019.

J. C. Osorio, A. Ni, J. E. Chaft, R. Pollina, M. K. Kasler et al., Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer, Ann Oncol, vol.01, issue.3, pp.583-592, 2017.

V. Panou, M. Gadiraju, A. Wolin, C. M. Weipert, E. Skarda et al., Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma, J Clin Oncol, vol.36, issue.28, pp.2863-71, 2018.

H. Pass, Surgery and mesothelioma: if not randomization, at least standardization and registration! Lung Cancer, janv, vol.71, issue.1, pp.1-2, 2011.

N. Patsoukis, D. Sari, and V. A. Boussiotis, PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A, Cell Cycle. 1 déc, vol.11, issue.23, pp.4305-4314, 2012.

L. Paz-ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümü? et al., Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.22, issue.21, pp.2040-51, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02345238

G. S. Phillips, J. Wu, M. D. Hellmann, M. A. Postow, N. A. Rizvi et al., Treatment Outcomes of Immune-Related Cutaneous Adverse Events, J Clin Oncol, 2019.

J. Pignon, H. Tribodet, G. V. Scagliotti, J. Douillard, F. A. Shepherd et al., Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J Clin Oncol. 20 juill, vol.26, issue.21, pp.3552-3561, 2008.

D. Planchard, S. Popat, K. Kerr, S. Novello, E. F. Smit et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.29, issue.Supplement_4, pp.192-237, 2018.

D. Planchard, S. Popat, K. Kerr, S. Novello, E. F. Smit et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 30 janv, 2019.

D. Planchard, B. Besse, H. Groen, P. Souquet, E. Quoix et al., Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an openlabel, multicentre phase 2 trial, Lancet Oncol. juill, vol.17, issue.7, pp.984-93, 2016.

D. Planchard, E. F. Smit, H. Groen, J. Mazieres, B. Besse et al., Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an openlabel, phase 2 trial, Lancet Oncol, vol.18, issue.10, pp.1307-1323, 2017.

N. Ready, M. D. Hellmann, M. M. Awad, G. A. Otterson, M. Gutierrez et al., First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers, J Clin Oncol. 20 avr, vol.37, issue.12, pp.992-1000, 2019.

M. Reck, H. Borghaei, O. Byrne, and K. J. , Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncology, vol.8

D. Sur,

M. Reck, A. Luft, A. Szczesna, L. Havel, S. Kim et al., Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer, J Clin Oncol, vol.01, issue.31, pp.3740-3748, 2016.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.10, issue.19, pp.1823-1856, 2016.

M. Reck, M. Schenker, K. H. Lee, M. Provencio, M. Nishio et al., Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial, Eur J Cancer. juill, vol.116, pp.137-184, 2019.

D. C. Rice, W. R. Smythe, Z. Liao, T. Guerrero, J. Y. Chang et al., Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma, Int J Radiat Oncol Biol Phys, vol.69, issue.2, pp.350-357, 2007.

D. Rice, V. Rusch, H. Pass, H. Asamura, T. Nakano et al., Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group, J Thorac Oncol. août, vol.6, issue.8, pp.1304-1316, 2011.

W. G. Richards, J. J. Godleski, B. Y. Yeap, J. M. Corson, L. R. Chirieac et al., Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases, Cancer. 15 mars, vol.116, issue.6, pp.1510-1517, 2010.

A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, vol.21, pp.255-65, 2017.

B. Robinson and R. A. Lake, Advances in malignant mesothelioma, N Engl J Med, vol.353, issue.15, pp.1591-603, 2005.

J. K. Sabari, G. C. Leonardi, C. A. Shu, R. Umeton, J. Montecalvo et al., PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers, Ann Oncol, vol.29, issue.10, pp.2085-91, 2018.

J. Salem, A. Manouchehri, M. Moey, B. Lebrun-vignes, L. Bastarache et al., Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study, Lancet Oncol, vol.19, issue.12, pp.1579-89, 2018.

A. Santoro, M. E. O'brien, R. A. Stahel, K. Nackaerts, P. Baas et al., Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program, J Thorac Oncol. juill, vol.3, issue.7, pp.756-63, 2008.

K. Sato, H. Akamatsu, E. Murakami, S. Sasaki, K. Kanai et al., Correlation between immunerelated adverse events and efficacy in non-small cell lung cancer treated with nivolumab, Lung Cancer, vol.115, pp.71-75, 2018.

G. V. Scagliotti, P. Parikh, J. Von-pawel, B. Biesma, J. Vansteenkiste et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol. 20 juill, vol.26, issue.21, pp.3543-51, 2008.

A. Scherpereel, J. Mazieres, L. Greillier, S. Lantuejoul, P. Dô et al., Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol. févr, vol.20, issue.2, pp.239-53, 2019.

J. H. Schiller, D. Harrington, C. P. Belani, C. Langer, A. Sandler et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med. 10 janv, vol.346, issue.2, pp.92-100, 2002.

R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science. 25 mars, vol.331, issue.6024, pp.1565-70, 2011.

A. H. Sharpe, E. J. Wherry, R. Ahmed, and G. J. Freeman, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, Nat Immunol. mars, vol.8, issue.3, pp.239-284, 2007.

A. T. Shaw, E. Felip, T. M. Bauer, B. Besse, A. Navarro et al., Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm firstin-man phase 1 trial, Lancet Oncol, vol.18, issue.12, pp.1590-1599, 2017.

K. Sheppard, L. J. Fitz, J. M. Lee, C. Benander, J. A. George et al., PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta, FEBS Lett. 10 sept, vol.574, issue.1-3, pp.37-41, 2004.

M. A. Socinski, R. M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy et al., Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med. 14 juin, vol.378, issue.24, pp.2288-301, 2018.

B. J. Solomon, T. Mok, D. Kim, Y. Wu, K. Nakagawa et al., First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer, New England Journal of Medicine. 4 déc, vol.371, issue.23, pp.2167-77, 2014.

J. Soria, A. Mauguen, M. Reck, A. B. Sandler, N. Saijo et al., Systematic review and metaanalysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as firstline treatment in patients with advanced non-small-cell lung cancer, Ann Oncol. janv, vol.24, issue.1, pp.20-30, 2013.

J. Soria, D. Tan, R. Chiari, Y. Wu, L. Paz-ares et al., First-line ceritinib versus platinumbased chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study, Lancet, vol.04, pp.917-946, 2017.

D. R. Spigel, C. Reynolds, D. Waterhouse, E. B. Garon, J. Chandler et al., Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation -Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370), J Thorac Oncol, vol.13, issue.5, pp.682-690, 2018.

J. Stebbing, T. Powles, K. Mcpherson, J. Shamash, P. Wells et al., The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma, Lung Cancer. janv, vol.63, issue.1, pp.94-101, 2009.

K. Suresh, K. J. Psoter, K. R. Voong, B. Shankar, P. M. Forde et al., Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy, J Thorac Oncol. mars, vol.14, issue.3, pp.494-502, 2019.

E. Taioli, A. S. Wolf, and R. M. Flores, Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma, Ann Thorac Surg. févr, vol.99, issue.2, pp.472-80, 2015.

D. P. Tashkin, Effects of marijuana smoking on the lung, Ann Am Thorac Soc. juin, vol.10, issue.3, pp.239-286, 2013.

S. Teraoka, D. Fujimoto, T. Morimoto, H. Kawachi, M. Ito et al., Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study, J Thorac Oncol, vol.12, issue.12, pp.1798-805, 2017.

A. Teufel, T. Zhan, N. Härtel, J. Bornschein, M. P. Ebert et al., Management of immune related adverse events induced by immune checkpoint inhibition, Cancer Lett. 1 août, vol.456, pp.80-87, 2019.

W. D. Travis, E. Brambilla, A. P. Burke, A. Marx, and A. G. Nicholson, Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart, J Thorac Oncol. sept, vol.10, issue.9, pp.1240-1242, 2015.

T. Treasure, L. Lang-lazdunski, D. Waller, J. M. Bliss, C. Tan et al., Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study, Lancet Oncol. août, vol.12, issue.8, pp.763-72, 2011.

J. Van-haarst, P. Baas, C. Manegold, J. H. Schouwink, J. A. Burgers et al., Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma, Br J Cancer. 1 févr, vol.86, issue.3, pp.342-347, 2002.

M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J. Smyth, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, vol.29, pp.235-71, 2011.

N. J. Vogelzang, J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel et al., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol. 15 juill, vol.21, issue.14, pp.2636-2680, 2003.

J. C. Wagner, C. A. Sleggs, and P. Marchand, Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province, Br J Ind Med, vol.17, pp.260-71, 1960.

I. Waldhauer and A. Steinle, NK cells and cancer immunosurveillance, Oncogene, vol.27, issue.45, pp.5932-5975, 2008.

D. Y. Wang, J. Salem, J. V. Cohen, S. Chandra, C. Menzer et al., Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, JAMA Oncol. 1 déc, vol.4, issue.12, pp.1721-1729, 2018.

G. Willimsky and T. Blankenstein, Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance, Nature. 1 sept, vol.437, issue.7055, pp.141-147, 2005.

S. M. Yoon, T. Shaikh, and M. Hallman, Therapeutic management options for stage III non-small cell lung cancer, World J Clin Oncol. 10 févr, vol.8, issue.1, pp.1-20, 2017.

G. Zalcman, J. Mazieres, J. Margery, L. Greillier, C. Audigier-valette et al., Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet. 2 avr, vol.387, pp.1405-1419, 2016.

P. A. Zucali, M. Simonelli, G. Michetti, M. Tiseo, G. L. Ceresoli et al., Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey, Lung Cancer. mars, vol.75, issue.3, pp.360-367, 2012.

M. Zukin, C. H. Barrios, J. R. Pereira, R. Ribeiro, M. Beato-ca-de et al., Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2, J Clin Oncol. 10 août, vol.31, issue.23, pp.2849-53, 2013.